A four-year agreement struck between Medicines for Ireland and the Irish government will offer “certainty for launch planning” for players in Ireland’s off-patent market thanks to a combination of clear long-term pricing mechanisms and drivers for generic and biosimilar uptake, the industry association believes.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?